Vonicog alfa

BIOLOGICAL2 trials

Sponsors

Baxalta now part of Shire, Takeda

Conditions

Von Willebrand DiseaseVon Willebrand Disease (VWD)

Phase 3

A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)

CompletedNCT02932618

Baxalta now part of ShireVon Willebrand Disease

Start: 2017-11-06End: 2026-04-17Updated: 2026-05-15

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

RecruitingNCT05582993

TakedaVon Willebrand Disease (VWD)

Start: 2024-11-06End: 2030-04-11Target: 24Updated: 2026-09-09

Related Papers

A retrospective analysis of the safety and effectiveness of recombinant von willebrand factor in children with von willebrand disease undergoing surgery

Blood2025-11-03

Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study

Blood2025-11-03

A Phase 3, Prospective, Open-Label, Uncontrolled, Multicenter Study on Efficacy and Safety of Prophylaxis with Recombinant Von Willebrand Factor in Children Diagnosed with Severe Von Willebrand Disease

Blood2024-11-05